| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TCEAL8 |
| Uniprot No | Q8IYN2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-117aa |
| 氨基酸序列 | MQKSCEENEG KPQNMPKAEE DRPLEDVPQE AEGNPQPSEE GVSQEAEGNP RGGPNQPGQG FKEDTPVRHL DPEEMIRGVD ELERLREEIR RVRNKFVMMH WKQRHSRSRP YPVCFRPLEH HHHHH |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TCEAL8重组蛋白的虚构参考文献示例(实际文献需通过学术数据库核实)：
---
1. **文献名称**: *TCEAL8重组蛋白的克隆表达及其在卵巢癌细胞中的抑癌功能研究*
**作者**: Zhang Y., et al.
**摘要**: 本研究成功构建了TCEAL8重组蛋白表达系统，通过体外实验证实其能抑制卵巢癌细胞增殖并诱导凋亡，提示其作为潜在肿瘤治疗靶点。
2. **文献名称**: *TCEAL8重组蛋白调控Wnt/β-catenin信号通路的分子机制*
**作者**: Smith J.L., et al.
**摘要**: 发现TCEAL8重组蛋白通过结合β-catenin抑制Wnt通路活性，降低下游靶基因表达，为靶向Wnt信号异常的癌症提供新策略。
3. **文献名称**: *基于TCEAL8重组蛋白的血清生物标志物在卵巢癌早期诊断中的应用*
**作者**: Lee H., et al.
**摘要**: 利用TCEAL8重组蛋白开发ELISA检测法，验证其在卵巢癌患者血清中高表达，灵敏度和特异性优于传统标志物CA-125.
4. **文献名称**: *TCEAL8重组蛋白的结构解析及其转录调控功能*
**作者**: Brown R.T., et al.
**摘要**: 通过X射线晶体学解析TCEAL8重组蛋白的三维结构，揭示其EF-hand结构域对DNA结合及转录抑制功能的关键作用。
---
**注**：以上为模拟内容，实际文献需查阅PubMed、Web of Science等数据库获取。研究关键词建议：TCEAL8 recombinant protein, cancer mechanisms, protein interaction。
**Background of TCEAL8 Recombinant Protein**
TCEAL8 (Transcription Elongation Factor A (SII)-Like 8) is a member of the TCEAL family, a group of nuclear proteins implicated in transcriptional regulation and chromatin remodeling. This family is characterized by conserved domains that interact with RNA polymerase II and other transcriptional machinery, potentially modulating gene expression during cellular processes such as differentiation, apoptosis, and cell cycle progression. TCEAL8. specifically, is encoded by a gene located on the X chromosome and contains a nuclear localization signal, suggesting its role in nuclear processes.
While the precise molecular function of TCEAL8 remains under investigation, studies suggest it may act as a transcriptional regulator, influencing pathways linked to oncogenesis and tumor suppression. Dysregulation of TCEAL8 has been observed in cancers, including ovarian and breast cancers, where its expression correlates with disease progression or therapeutic resistance. For instance, reduced TCEAL8 levels have been associated with enhanced cancer cell proliferation and metastasis, implying potential tumor-suppressive activity.
Recombinant TCEAL8 protein is engineered for in vitro and in vivo studies to elucidate its biological roles. Produced via bacterial or mammalian expression systems, the purified protein retains functional domains necessary for binding nucleic acids or partner proteins. Researchers utilize it in assays such as chromatin immunoprecipitation (ChIP), protein-protein interaction studies, and functional genomics to map its involvement in transcriptional networks.
Current research focuses on understanding how TCEAL8 interfaces with signaling pathways like p53 or Wnt/β-catenin, which are critical in cancer biology. Its recombinant form also serves as a tool for developing targeted therapies or biomarkers. Despite progress, comprehensive mechanistic insights into TCEAL8’s regulatory functions and its therapeutic potential remain areas of active exploration.
×
